Vivos Inc (RDGL)

[RobbinGood]

WALLnut! BOOM! MUST READ! U nailed it! Notice in your post this part.... follow me here, you tell me we haven't found the golden goose here, read the press release below about the name change, symbol change, going to the OTCQB and then a national exchange.
ALL OF THIS HAPPENS THE SAME MONTH WE GET FDA CONFIRMATION!
Vivos Receives FDA Confirmation of RadioGel Device Classification for Animal Skin Cancer Therapy
January 30, 2018
https://irdirect.net/prviewer/release/id/2916771

So WALLnut, in your post you mention this,

1) It says "Vivos Inc.", well until 01/02/2018, this company was known as Advanced Medical Isotope Corporation symbol ADMD. Down below you will see i posted links to SEC filings, OTCMarkets.com and the actual press release changing the name to "Vivos Inc" symbol $RDGL. Well on the website link you posted here it says ""Vivos Inc. has obtained an exclusive license to eight (8) patents related to RadioGel™ device technology for use in high-dose radiation therapy."
It does not say the old name of "Advanced Radio Isotope Corp." but it says the new name of the company, "Vivos Inc" and we have AN EXCLUSIVE LICENSE TO PATENTS RELATED TO RADIOGEL".
And as StockRoomBully so kindly point out, who owns those patents, a 6.2 billion dollar company named Battelle. BOOOOOOOOOOOOOOOOM!

"Vivos Inc. has obtained an exclusive license to eight (8) patents related to RadioGel™ device technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and Vivos announced in February 2011. The Agreement grants Vivos an exclusive license to make, have made, use and sell RadioGel™ as a device. Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 particles and the polymer gel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost."
https://www.radiogel.com/radiogel/

2) Corporate Actions
Symbol Changes
ACTION TYPE EFFECTIVE DATE SYMBOL DESCRIPTION
Symbol Change 01/02/2018 RDGL Symbol change from ADMD to RDGL

3) ADVANCED MEDICAL ISOTOPE CORPORATION
10-Q 11/13/2017 09/30/2017 https://www.otcmarkets.com/filing/html?id=12374212&guid=S5SoUKebBfac43h

4) Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
Published 9:01 AM ET Tue, 2 Jan 2018
Globe Newswire
https://www.cnbc.com/2018/01/02/globe-newswire-advanced-medical-isotope-corporation-admd-announces-corporate-name-change-to-vivos-inc-and-ticker-symbol-change-to-rdgl.html

Richland, WA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation (OTCPink: RDGL) announced today that it has changed its name to Vivos Inc., and that its shares are scheduled to trade under the new symbol, RDGL, on the OTC Markets on January 2, 2018. Both of these changes represent a rebranding of the Company to reflect its focus on RadioGelTM for the treatment of skin cancer. Our new name, which reflects the giving of life, captures the essence of our Company mission. In addition to these rebranding efforts, management anticipates qualifying the Company’s common stock for quotation on the OTCQB in the near-term with the longer-term goal of a listing on a national exchange.

Mike Korenko, CEO, said “Our new name better reflects the description of our current and near-term product and markets. After obtaining approval to treat skin cancer, we intend to grow by expanding the cancers that we treat over time. We will also consider non-cancer applications, such as treating infections imbedded in bones that currently lead to amputation, which can occur is diabetic patients.”

Mr. Korenko continued, “We are very excited about the prospects for RadioGelTM to treat animals and humans. We continue to believe that our Company’s valuation does not currently reflect the underlying value of RadioGelTM and the large market opportunity in both the animal and human market. We appreciate the continued support of our shareholders and our note holders, who as previously reported on Form 8-K, agreed to eliminate all variable price conversion through April 15, 2018. We are excited about 2018 and maintain a firm belief in our mission to provide patient friendly solutions utilizing the unique RadioGel™ technology and to grow shareholder value.”

About Vivos Inc. (OTCPink: RDGL)

The strategic market sector of RDGL is isotope applications. Currently, the Company is engaged in the
development of RadioGelTM, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.

The Company is engaging the FDA for permission to use RadioGelTM for the treatment of advanced basal and squamous cell skin cancers. The IsoPet Solutions division of RDGL is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. RDGL is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGelTM to private animal clinics.

The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGelTM in other countries.

About RadioGel™

RadioGelTM is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.

“You do not want to give Jeff Bezos a seven-year head start.”
Hear what else Buffett has to say

RadioGelTM also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.

Please click the following link to view our website: https://www.radiogel.com/